Prognosis of relapsed cases after CAR-T therapy for relapsed and refractory follicular lymphoma (FL) and functional analysis of CAR-T cells(JSCT CART24 Follow-up)

Prognosis of relapsed cases after CAR-T therapy for relapsed and refractory follicular lymphoma (FL) and functional analysis of CAR-T cells - JSCT CART24 Follow-up

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057306

Enrollment

Registered

2025-03-17

Start date

2025-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

follicular lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with follicular lymphoma (FL) who have undergone CAR-T therapy and are scheduled to receive anticancer drugs as a next treatment due to recurrence or incurable disease. 2. Patients aged 18 years or older at the time of obtaining consent. 3. Patients who have been informed of the contents of this study and have given written consent.

Exclusion criteria

Exclusion criteria: If the doctor in charge judges you to be inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
Of the 20 cases of FL that were determined to be recurrent or refractory after undergoing CAR-T therapy, two cases in the tazemetostat group and two cases in the non-tazemetostat group will have peripheral blood samples taken before and after the start of the next treatment (just before the start of the next treatment after determining that the patient is recurrent or refractory, one month after administration, and three to six months after administration) to perform single cell RNA analysis and ATAC-seq.	—

Measure

Time frame

Of the 20 cases of FL that were determined to be recurrent or refractory after undergoing CAR-T therapy, two cases in the tazemetostat group and two cases in the non-tazemetostat group will have peripheral blood samples taken before and after the start of the next treatment (just before the start of the next treatment after determining that the patient is recurrent or refractory, one month after administration, and three to six months after administration) to perform single cell RNA analysis and ATAC-seq.

—

Secondary

Measure	Time frame
1. Exploratory efficacy evaluation Complete response rate (CR rate) Overall response rate (ORR) Duration of response rate (DOR rate) Progression-free survival rate (PFS rate) Overall survival rate (OS rate) 2 Safety evaluation	—

Countries

Japan

Contacts

Public Contacttoyohiro kawano

JSCT office

jsct-office@umin.ac.jp042-505-4251

Outcome results